Today's post from peoplespharmacy.com (see link below) is a bit of a wake-up call for people who regularly use vitamin supplements - too much of a particular vitamin can have the opposite effect to that which you hoped for. You will also see Vitamin B widely recommended as a help when you have neuropathic problems but that is generally B12 and even then, it should only be used when you have a deficiency already. Doctors are sometimes reluctant to routinely test for vitamin deficiencies but it's not that difficult and in the case of neuropathy, it can provide important information. The lesson here is that you should find out exactly what you're lacking in the vitamin department and then supplement as necessary (or improve your diet). Overdosing on a particular vitamin can be dangerous and even checking how much (vitamin B types in this case) is in your daily multi-vitamin may prevent you taking in too much. As a general point, if you take Vitamin B12 supplements, don't forget that you need folic acid too, in order for the body to absorb it efficiently. Many products have folic acid 'in-built' but if not, you will need folic acid supplements to achieve the right effect.
In general, always get the advice of your docotr or a qualified nutritionist before deciding to supplement your diet - it could save you both money and health problems.
ScienceDaily (Aug. 7, 2012)
Cannabis-based medications have been demonstrated to relieve pain. Cannabis medications can be used in patients whose symptoms are not adequately alleviated by conventional treatment. The indications are muscle spasms, nausea and vomiting as a result of chemotherapy, loss of appetite in HIV/Aids, and neuropathic pain.
This is the conclusion drawn by Franjo Grotenhermen and Kirsten Müller-Vahl in issue 29-30 of Deutsches Ärzteblatt International.
The clinical effect of the various cannabis-based medications rests primarily on activation of endogenous cannabinoid receptors. Consumption of therapeutic amounts by adults does not lead to irreversible cognitive impairment. The risk is much greater, however, in children and adolescents (particularly before puberty), even at therapeutic doses.
Over 100 controlled trials of the effects of cannabinoids in various indications have been carried out since 1975. The positive results have led to official licensing of cannabis-based medications in many countries. In Germany, a cannabis extract was approved in 2011 for treatment of spasticity in multiple sclerosis. In June 2012 the Federal Joint Committee (the highest decision-making body for the joint self-government of physicians, dentists, hospitals and health insurance funds in Germany) pronounced that the cannabis extract showed a slight additional benefit for this indication and granted a temporary license until 2015.